Vistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update

Advancing potential to execute Phase 3 development plan for fasedienol in social anxiety disorder following constructive FDA feedback, with disciplined capital management and strategic flexibilitySOUTH SAN FRANCISCO, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Vistagen NASDAQ:VTGN, a late clinical-st…